Acute congestive heart failure (including acute exacerbation of chronic heart failure) patietnts
Conditions
Interventions
Tolvaptan group: 7.5-15mg/day oral administration
Carperitide group: 0.0125-0.025&
micro
g/kg/min continuous intravenous administration (-0.2&
g/kg depending on the condition)
Sponsors
Fukushima Medical University
Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients with fluid retention in congestive heart failure (2) Patients who were hospitalized for treatment of heart failure
Exclusion criteria
Exclusion criteria: (1) Patients with circulatory assist device (2) Acute myocardial infarction (3) Patients with dehydration (4) Severe hypotension or cardiogenic shock (5) Patients with right heart ventricular infarction (6) Patients are considered undesirable rapid decrease in blood flow circulation (7) Patietns with hypersensitivity to study drug (8) Anuric patients (9) Insensitivity to the thirst or difficult for the water intake (10) Hypernatremia (serum Na>147mEq/L) (11) Pregnant woman, lactational woman, patients may be willing to be pregnant or are pregnant (12) In addition, patients were judged as inadequate by physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Daily urine volume of first, second, third, fourth, seventh, and day 14th after admission (or dicharge) | — |
Secondary
| Measure | Time frame |
|---|---|
| Body weight of subjective symptoms | — |
Countries
Japan
Contacts
Public ContactSatoshi Suzuki
Fukushima Medical University Deaprtment of Cardiology and Hematology
Outcome results
None listed